trending Market Intelligence /marketintelligence/en/news-insights/trending/m1zmf_l0N9DjZj3Awv6NCw2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Eli Lilly cancer drug meets endpoint in phase 3 trial

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Eli Lilly cancer drug meets endpoint in phase 3 trial

Eli Lilly & Co.'s Cyramza met its primary endpoint in a phase 3 trial involving patients with a certain kind of bladder cancer.

The drug, in combination with docetaxel, showed that urothelial carcinoma patients whose disease progressed on or after platinum-based chemotherapy achieved superior progression-free survival when compared to chemotherapy.

Although the primary endpoint has been met, Lilly anticipates that overall survival results are likely to be required for global regulatory submissions.

Final overall survival results are expected in mid-2018.

Cyramza is already approved for certain types of cancer, including metastatic non-small cell lung cancer in combination with docetaxel.